Jump to content

Benlysta: first targeted lupus treatment


Recommended Posts

  • Admin

Benlysta: first targeted lupus treatment

01 November 2011, 9:14am

Benlysta (belimumab) is licensed as add-on therapy in patients with autoantibody-positive systemic lupus erythematosus (SLE) who have high disease activity despite standard treatment.

Benlysta must be administered in hospital


Belimumab is a monoclonal antibody specific for the soluble human B lymphocyte stimulator protein, BLyS. It inhibits the differentiation of B cells into antibody-producing plasma cells.1


Two pivotal randomised trials showed that the addition of belimumab to standard care improves control of disease activity in SLE.

BLISS-76 and BLISS-52 enrolled seropositive SLE patients (n=819 and n=865, respectively). In addition to standard treatment, patients received belimumab 10mg/kg or 1mg/kg or placebo by intravenous infusion on days 0, 14 and 28, and every 28 days thereafter.2,3

In both studies, response rates at week 52 (as determined by the SLE Responder Index) were significantly higher in patients treated with the 10mg/kg dose of belimumab than in patients who received placebo. In a pooled analysis of the two studies, the combined response rate was 51% for belimumab 10mg/kg compared with 39% for placebo (p<0.0001).2,3

Belimumab was well tolerated in both studies, with rates of adverse events similar to placebo.2,3


View Benlysta drug record

Further information: GlaxoSmithKline

Link to comment
Share on other sites

This topic is now closed to further replies.
  • Create New...

Important Information